Also known as QVA149, Onbrez Breezhaler belongs to a
new type of dual-action treatments that are expected by analysts to
become major sellers.
The Phase IV study in patients with moderate chronic obstructive
pulmonary disease (COPD) found Novartis' once-daily drug showed
similar benefits in reducing shortness of breath as GSK's Seretide,
which must be taken twice daily.
Around 210 million people worldwide suffer from COPD, a disease that
causes breathing trouble and chronic coughing, and is sometimes
(Reporting by Caroline Copley; editing by Edwina Gibbs)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.